Circadian Technologies has success in macular degeneration mouse trials – Proactive Investors Australia

Proactive Investors Australia
Circadian Technologies (ASX: CIR, OTCQX: CKDXY) should trade firmer after its subsidiary Opthea highlighted the success of its drug development candidate, OPT-302, in inhibiting wet advanced macular degeneration progression in mice. Opthea and its …

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment